Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.
Antineoplastic Agents
/ pharmacology
Cell Line, Tumor
Cell Survival
/ drug effects
Cisplatin
/ pharmacology
DNA Damage
/ drug effects
Epithelial Cells
/ drug effects
Humans
Ligands
MCF-7 Cells
Mitochondria
/ drug effects
Mitochondrial Membranes
/ drug effects
Organoplatinum Compounds
/ pharmacology
Oxaliplatin
/ pharmacology
Prodrugs
/ pharmacology
Reactive Oxygen Species
/ metabolism
DNA damage
Pt(IV) prodrugs
cisplatin
cytotoxicity
oxaliplatin
translocator protein
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
03 08 2020
03 08 2020
Historique:
pubmed:
7
7
2020
medline:
29
6
2021
entrez:
7
7
2020
Statut:
ppublish
Résumé
The design, synthesis, characterization, and biological activity of a series of platinum(IV) prodrugs containing the axial ligand 3-(4-phenylquinazoline-2-carboxamido)propanoate (
Identifiants
pubmed: 32628022
doi: 10.1021/acs.molpharmaceut.0c00417
doi:
Substances chimiques
Antineoplastic Agents
0
Ligands
0
Organoplatinum Compounds
0
Prodrugs
0
Reactive Oxygen Species
0
Oxaliplatin
04ZR38536J
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM